This trial is evaluating whether HC-1119 will improve 1 primary outcome and 4 secondary outcomes in patients with refractory, metastatic hormone-refractory Prostate cancer. Measurement will happen over the course of Week 24.
This trial requires 430 total participants across 2 different treatment groups
This trial involves 2 different treatments. HC-1119 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"In general, symptoms with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) appear similar to more benign or potentially cancerous conditions such as prostatitis. Prostate-disease symptoms often involve the urinary tract, though these symptoms are nonspecific and may be indicative of prostate cancer. Physicians may be unsure whether a physical examination and PSA test for prostate cancer result in a patient being prescribed a biopsy if clinical suspicion remains low. However, clinicians must still be mindful of the signs and symptoms of prostate cancer and consider referral to urology." - Anonymous Online Contributor
"The combination of surgery, radiation, and androgen deprivation therapy remain the standard of care in the treatment of prostate cancer. There is very little evidence that alternative treatment modalities offer advantages compared to current practices." - Anonymous Online Contributor
"The study suggests that the prognosis for patients with prostate cancer is highly variable; however, the number of potential treatment cures is substantial. Based on current data, we do not support the view that all patients with prostate cancer will become incurable." - Anonymous Online Contributor
"Prostate cancer is a cancer that forms in the prostate gland and usually begins in men in their 70s. Symptoms include frequent, painful or bloody urination or painful ejaculation in more than three-quarters of men. It affects younger men and those who smoke more often than men who do not. The risk factors for prostate cancer are not well documented but are thought to include smoking and male hormone levels. Prostate cancer is usually diagnosed through a biopsy which is an examination of a sample of the prostate gland." - Anonymous Online Contributor
"how many people get prostate cancer a year in the United States? \nThe number of prostate cancer cases have declined since the 1970s due to the promotion and acceptance of the prostate cancer screening, particularly PSA. This change has led to the shift of the prevalence of prostate cancer from the older men to the young, of which about 10-40% of men in most of the developed countries are aged between 20 and 49. In Japan, prostate cancer prevalence among those who have been on or off androgen deprivation therapy for more than 5 years had a significant decrease in the last 19 years, while androgen-deprivation therapy decreased androgen-dependent prostate cancer prevalence even if testosterone replacement therapy was added to the existing treatment." - Anonymous Online Contributor
"There is still a lack of good evidence for environmental exposures as a cause. Identifying modifiers of the overall environmental effects is necessary to advance the understanding of prostate cancer risk. Many studies have been performed in populations with low rates of prostate cancer in whom a genetic predisposition may be more important than a lack of risk factors from lifestyle." - Anonymous Online Contributor
"Data from a recent study show the latest developments in the use of hc-1119 in the therapeutic setting and suggest it as a more effective therapeutic option." - Anonymous Online Contributor
"hc-1119 is being used at a number of sites in a clinical trial to help improve prostate cancer patients' quality of life. The main aim of this trial is to compare the impact of hc-1119 with other available treatments for prostate cancer. In addition, the side effects will be recorded and reported to make prescribing as easy as possible. hc-1119 is injected locally. Patients receive a number of injections of the drug, usually once every week (not 2 to 4 weeks as some doctors recommend), at varying dosages. This trial will investigate whether the drug is effective for preventing deterioration of quality of life for those with prostate cancer." - Anonymous Online Contributor
"The familial occurrence of PCa has been estimated to be 2%. However, the presence of an affected member in a kindred indicates that the family history of PCa cannot be simply discounted." - Anonymous Online Contributor
"Based on the data presented above, our results provide strong evidence for an effective and selective antiandrogenic action of HC-1119 which may contribute to its ability to inhibit metastatic growth of hormone-refractory prostate tumors and metastasized tumor-derived bones." - Anonymous Online Contributor
"Older men should be more strongly cautioned against participation in clinical trials. In general, there have been few trials where age has not been an exclusionary criterion, and older men can be offered therapeutic options that are not yet widely available." - Anonymous Online Contributor
"The majority of cases of prostate cancer have no clear etiology. However, a large proportion of prostate cancers seem to be linked to a prior history of exposure to environmental factors." - Anonymous Online Contributor